On the stock market since 2024, it operates in the world of health and science. It has 55 employees. Now — the numbers.
This is an established company with proven profits.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Average growth of 36% a year over the last 4 years. Red columns mark years that ended in a loss.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
Clearly below the class average.
The price looks reasonable next to what the company earns.
There is growth, but not at top-of-the-class tempo.
Clearly below the class average.
Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
An investor who bought at the very peak is down 93% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
The net profit margin is 27% — still a thick cushion, though costs have been eating into it lately.
Over the last 3 years, sales grew about 38% a year on average.
Over the last 12 months, company executives reported 23 buys and 20 sells. Management buying with its own money is usually read as a good sign.
Buyers haven’t stepped back in yet; the price hasn’t found its footing. Report-card grade: 8/100. For a turnaround signal, the stock first needs to close the gap with the market.
The balance sheet offers little cushion against a rough stretch. Report-card grade: 20/100.
On our five-subject report card, SNWV sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: SNWV is an established business that has proven its profits for years. The real debate here isn’t the price — it’s whether the company can keep up this pace.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.